AddedRisk Factors
Any clinical trial may fail to produce results satisfactory to the FDA or foreign regulatory authorities; moreover, these regulatory authorities have substantial discretion and influence over clinical trial design and conduct, as well as the drug approval process. As such, approval outcomes are difficult to predict. Even if late-state, registrational clinical trials for our new products are positive, the FDA or foreign regulatory authorities may refuse to approve any NDA or sNDA or their foreign equivalents, or require additional preclinical, clinical, safety or other non-clinical studies.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedRisk Factors
The FDA has also been tightening the requirements for confirmatory studies for drugs approved via accelerated approval under additional authorities the FDA received in Section 3210 of the FDORA (incorporated in Section 3222 of the
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedRisk Factors
The FDA may also choose to convene an advisory committee of independent experts to evaluate the adequacy of the safety and efficacy data supporting a drug candidate’s approvability. The outcome of such advisory committee meetings is inherently uncertain and may have a significant impact on the likelihood, timing, and scope of regulatory approval for our product candidates. In addition, while influential, advisory committee decisions are not binding on the FDA and there have been instances in the oncology space where the FDA chose not to take an advisory committee’s recommendation. There is also the risk that an advisory committee may recommend against approval, suggest a narrower indication, or require additional studies or safety labeling, and the FDA may or may not accept these recommendations. This uncertainty is heightened by recent leadership changes at OCE, which may result in shifts in regulatory priorities, review standards, or interpretations of clinical data, further complicating the approval process. As a result, the regulatory pathway for our drug candidates may be even more unpredictable, complex, and lengthy, and any adverse outcome in the advisory committee process or final FDA decision could materially and adversely affect our business, financial condition, results of operations, and prospects.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedRisk Factors
The U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, the United States has announced tariffs on many goods imported from specified nations. In addition, there are currently discussions concerning potential increased tariffs for pharmaceutical products, which may impact our supply chain and create uncertainty in the broader pharmaceutical industry. While certain tariffs have been suspended, modified or temporarily reduced, we cannot predict the results of the U.S. government’s trade negotiations or the outcome of ongoing legal challenges to specific tariff policies. Changes in U.S. trade policy, including recently announced tariffs, related to countries where we or our suppliers operate could result in increased costs for raw materials, components, or finished goods for us, or challenges for our third-party contract manufacturers, distributors and suppliers to continue to meet demands for our products at current prices. These cost increases may reduce our margins, require us to raise prices, or make our products less competitive in the marketplace. Additionally, retaliatory tariffs imposed by other countries on U.S. exports could adversely impact demand for our products in international markets or increase the costs of conducting business. If we are unable to mitigate these risks through supply chain adjustments, pricing strategies, or other measures, our financial performance and growth prospects could be negatively affected.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RemovedRisk Factors
There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders and sub-regulatory guidance, that may impact pricing for pharmaceutical products. These initiatives include, among others:
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
and the length of time required to enroll eligible patients. Any delay could limit our ability to generate revenues, cause us to incur additional expenses and cause the market price of our common stock to decline significantly.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our third-party contract manufacturers may not be able to produce or deliver material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion, and also impact our current and future business arrangements with third parties, including various healthcare
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, as amended by the CPRA, as well as the GDPR, we could be subject to sanctions or other penalties, litigation, an increase in our cost of doing business and questions concerning the validity of our data processing activities, including clinical trials.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedRisk Factors
compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RewordedRisk Factors
Likewise, as a result of significant changes in U.S. or global political and macroeconomic conditions, including the potential for local and/or global economic downturn or recession, inflation, fluctuating interest rates, as well as policies governing foreign trade, including tariffs or the imposition of new tariffs, trade (including tariffs) wars, barriers, restrictions, or threats of such actions and the related uncertainty thereof, and healthcare spending and delivery, or the ongoing hostilities conflicts between Russia and Ukraine and in Eastern Europe and the Middle East, or the political, economic and social instability in Venezuela, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we have not yet experienced significant production delays or seen significant impairment to our supply chain as a result of the ongoing hostilities conflicts between Russia and Ukraine and in Eastern Europe and the Middle East East, the political, economic and social instability in Venezuela or other global events, including as a result of tariffs or the imposition of new tariffs, trade wars, barriers, restrictions, or threats of such actions and the related uncertainty thereof, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to lack of capacity or resources, facility closures and other hardships as a result of these types of global events, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our preclinical, clinical or commercial products.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
Due to general uncertainty with respect to this litigation and in the current regulatory and healthcare policy environment, and specifically regarding positions that the Trump Administration may take with respect to these issues, we are unable to predict the impact of any future legislative, regulatory, third-party payer payer, or policy actions, including potential cost containment and healthcare reform measures. actions at this time.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
It is possible that MSN or Sun MSN, Azurity, Handa, or other companies, following will obtain FDA approval of an ANDA or 505(b)(2) NDA, could and introduce generic or otherwise competitor versions of our marketed products cabozantinib before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. unenforceable.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
Moreover, in September 2023, the FTC issued a policy statement, supported by the FDA, warning brand pharmaceutical companies that they could face legal action under the FTC Act if they improperly list patents in the Orange Book, and it subsequently initiated challenges against patents held by brand pharmaceutical companies and listed in the Orange Book
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
At the In addition to such drug pricing and transparency matters, other state level, legislatures legislative and regulatory agencies have increasingly passed legislation and implemented regulations initiatives include proposals designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, advance notices of price increases, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
(individually For example, we received Paragraph IV certification notice letters from MSN, Teva, Cipla, Sun, and collectively referred to as Cipla) and Sun Biocon concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even We cannot be certain that these clinical trials will demonstrate adequate safety and efficacy to receive regulatory approval, and even if the required regulatory approvals to market CABOMETYX for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional such indications.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, certain a growing number of states have also enacted laws requiring manufacturers to provide the 340B Program pricing through contract pharmacy arrangements; these laws are also being challenged in ongoing litigation. arrangements, and additional states may adopt similar laws.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are unable to maintain or scale our commercial function appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Many Some of our competitors have greater capital resources, larger research and development staff and facilities, deeper organizational regulatory experience and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Depending on the outcome of the ongoing litigation or any specific proceedings involving us, however, we may be required to modify or suspend our 340B Program Integrity Initiative.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Furthermore, all the majority of our employees are employed “at will” and, therefore, may leave our employment at any time.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
There have also been proposals from the current U.S. administration that aim to lower prescription drug costs, both through formal regulatory action and by encouraging voluntary compliance from manufacturers. These proposals include efforts to equalize the prices of drugs in the U.S. with the prices of those drugs in other developed countries (also known as MFN drug pricing policy), as well as efforts to sell prescription drugs directly to consumers. In 2025, an executive order issued by the White House directed HHS and other federal agencies to implement MFN pricing through new models and potential regulatory actions. CMS has announced a pilot program in this regard for the Medicaid Program, but the full scope, timing, and impact of these initiatives remain uncertain. Adoption of these and other controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit reimbursement of pharmaceuticals. As a result, the business case for any product that receives regulatory approval for commercial sale in the U.S. may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
We also have three ongoing pivotal trials, two evaluating zanzalintinib in combination with ICIs and one evaluating zanzalintinib as a monotherapy. Our first such trial, STELLAR-303, was initiated in June 2022 and is evaluating zanzalintinib in combination with atezolizumab versus regorafenib in patients with metastatic, refractory non-MSI-H/dMMR CRC. In June 2025, we announced positive top-line results demonstrating a statistically significant improvement in OS versus regorafenib
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
in the ITT population, and in October 2025, announced that the study demonstrated a 20% reduction in the risk of death versus regorafenib in the ITT population at the final analysis (stratified hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.69-0.93; P=0.0045). At a prespecified interim analysis, data pertaining to the other dual primary endpoint, OS in patients without liver metastases, showed a trend in OS favoring the combination (15.9 months versus 12.8 months; stratified HR: 0.79; 95% CI: 0.61-1.03; P=0.0875) at a median follow-up of 16.8 months. Detailed findings from the study, including OS and PFS in the ITT population and in the subset of patients without liver metastases, were presented at ESMO 2025 and simultaneously published in The Lancet. The trial will proceed to the planned final analysis for the dual primary endpoint of OS in patients without liver metastases, expected in mid-2026, depending on event rates. In December 2025, we submitted a NDA to the FDA for zanzalintinib in combination with atezolizumab for the treatment of previously treated metastatic colorectal cancer. In January 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a PDUFA target action date of December 3, 2026.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
The second pivotal trial, STELLAR-304, was initiated in December 2022 and is evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced nccRCC. We expect top-line results in mid-2026, depending on event rates.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
In June 2025, we initiated STELLAR-311, a phase 2/3 pivotal trial evaluating zanzalintinib versus everolimus in patients with advanced NET, regardless of site of origin, who had received up to one prior line of therapy. The primary endpoint of the trial is PFS per RECIST 1.1 as assessed by blinded independent central review. Enrollment is currently ongoing.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
Beyond STELLAR-001, STELLAR-002, STELLAR-303, STELLAR-304 and STELLAR-311, we intend to initiate additional early-stage and pivotal trials evaluating zanzalintinib across a broad array of potential future indications, including: STELLAR-201, a planned, single-arm phase 2 study that will evaluate zanzalintinib in patients with Grade I/II/III meningioma with relapse or progression following surgery and radiation, or who are not candidates for radiation/surgery, anticipated to commence in the first half of 2026, and STELLAR-316, a planned phase 3 pivotal trial, in collaboration with Natera, which we anticipate will commence in mid-2026. STELLAR-316 will evaluate zanzalintinib, with and without an ICI, in patients with resected stage II/III CRC who, following completion of definitive therapy, have tested positive for MRD+ and have no radiographic evidence of disease. Natera will provide its Signatera™ assay to identify MRD+ for trial enrollment.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
program. In December 2023, we initiated STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab, an anti-PD-1 ICI developed by Merck & Co., versus placebo in combination with pembrolizumab in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck. Based on our evaluation of emerging data from the phase 2 portion of STELLAR-305, competition in this indication, and assessment of other, potentially larger, commercial opportunities, in July 2025 we announced that the study will not proceed to phase 3.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
We have made significant progress under our research collaborations and in-licensing arrangements and believe we will continue to do so in 2026 and in future years. For example, in April 2025, we initiated the phase 1 study of XB628, a first-in-class bispecific antibody discovered, in part, in collaboration with Invenra, and in August 2025, we initiated a phase 1 study of XB371, a next-generation tissue factor-targeting ADC with a topoisomerase inhibitor payload, which was discovered, in part, in collaboration with Catalent. As part of our rational and disciplined approach to investment, we have decided to discontinue further development of the XB064 and XB033 programs.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
•In February 2025, we announced final five-year follow-up results from the CheckMate -9ER trial at the ASCO Genitourinary Cancers Symposium.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
•In March 2025, we announced FDA Approval of CABOMETYX for patients with previously treated advanced NET.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
•In June 2025, we announced positive top-line results from the STELLAR-303 phase 3 pivotal trial that the study met one of its dual primary endpoints, OS in the ITT population, with the OS benefit of the zanzalintinib and atezolizumab combination consistently observed across pre-specified subgroups.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
AddedMD&A
•In June and July 2025, the USPTO declined to institute Azurity’s inter partes review of U.S. Patent Nos. 11,298,349 and 12,128,039, respectively.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RemovedMD&A
discount will be 1% in 2025 and will further increase according to a schedule set by CMS until we are required to pay the full 20% discount paid by other manufacturers in 2031.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
We are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could potentially benefit from this medicine. In August 2023, we announced positive results from CABINET, a phase 3 pivotal study that evaluated cabozantinib versus placebo in patients with NET who experienced progression after prior systemic therapy in two independently powered cohorts: one for patients with advanced pNET and another for patients with advanced epNET. The trial was unblinded and stopped early due to the dramatic improvement in efficacy with respect to the primary endpoint of PFS observed at interim analysis. Data from CABINET demonstrated that cabozantinib substantially prolonged PFS as assessed by blinded independent central review in both pNET and epNET cohorts, and that the safety profile of cabozantinib observed in the trial was consistent with its known safety profile. In August 2024, we announced that the FDA had accepted our sNDA seeking approval for cabozantinib to treat adult patients with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pNET or epNET, granted standard review in the U.S., and assigned a PDUFA target action date of April 3, 2025. The FDA also granted orphan drug designation to cabozantinib for the treatment of pNET. Detailed final results from CABINET were presented during the NETs and Endocrine Tumours Proffered Paper Session at the ESMO 2024 and were concurrently published in NEJM. In November 2024, we announced that our sNDA would be discussed at an ODAC meeting in March 2025; however, in January 2025, we announced that the FDA had notified us that our sNDA would no longer be the subject of discussion at an ODAC. CABINET was conducted by the Alliance through our CRADA with the NCI-CTEP, which along with our investigator-sponsored trial program, provides an avenue for independent investigations of cabozantinib. The Alliance presented results from a subgroup analysis of patients in the epNET cohort with advanced gastrointestinal NET in CABINET at the ASCO GI 2025.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
Building on preclinical and clinical observations that cabozantinib in combination with ICIs may promote a more immune-permissive tumor environment, we have initiated several pivotal studies to further explore these combination regimens, including collaborations with Roche and BMS. In August 2023, we announced positive top-line results from CONTACT-02, a phase 3 pivotal trial sponsored by us and co-funded by Roche, evaluating the combination of cabozantinib and Roche’s ICI, atezolizumab, versus a second NHT in patients with measurable, extra-pelvic mCRPC who have progressed after treatment with one prior NHT. The trial met one of two primary endpoints, demonstrating a statistically significant improvement in PFS in the predefined PFS intent-to-treat population (i.e., the first 400 randomized patients), and these data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in January 2024. For the second primary endpoint of OS, the final analysis for CONTACT-02, which was presented during the GU Tumours Proffered Paper Session at ESMO 2024, showed a trend that favored the combination of cabozantinib and atezolizumab but was not statistically significant. Of note, the trend in OS benefit was consistently observed in key subgroups, including in patients with liver metastases—a subgroup of mCRPC patients with the poorest prognosis in need of new treatment options, and one we anticipate will grow in the coming years. The safety profile observed in the trial was reflective of the known safety profiles for each single agent and was consistent with the known tolerability profile of approved ICI-TKI combinations in advanced solid tumors. We continue to evaluate the timing of a potential regulatory submission with the FDA. Both Ipsen and Takeda opted into and are co-funding the trial.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
In August 2024, we announced the final analysis for the secondary endpoint of OS for COSMIC-313, a phase 3 pivotal trial evaluating the combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. At the final analysis, the experimental arm did not demonstrate an OS benefit over the control arm. Based on these results and the evolution of the
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
first-line RCC treatment landscape since this study was initiated in May 2019, Exelixis will not pursue marketing authorization for COSMIC-313. Data from the final analysis of OS in COSMIC-313 will be presented at the ASCO GU 2025.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
We have also initiated three pivotal trials evaluating zanzalintinib in combination with ICIs. Our first such trial, STELLAR-303, was initiated in June 2022 and is evaluating zanzalintinib in combination with atezolizumab versus regorafenib in patients with metastatic, refractory non-microsatellite instability-high or non-mismatch repair-deficient CRC; we announced completion of enrollment into STELLAR-303 in August 2024, and preliminary results are expected in the second half of 2025. The second pivotal trial, STELLAR-304, was initiated in December 2022 and is evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced nccRCC; we anticipate completing enrollment into STELLAR-304 by mid-2025. In December 2023, we initiated STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab, an anti-PD-1 ICI developed by Merck & Co., versus monotherapy pembrolizumab in patients with previously untreated PD-L1-positive recurrent or metastatic SCCHN; enrollment into STELLAR-305 is ongoing. We intend to initiate additional pivotal trials evaluating zanzalintinib across a broad array of future potential indications, including in STELLAR-311, a planned phase 3 pivotal trial evaluating zanzalintinib versus everolimus as a first oral therapy in patients with advanced NET, regardless of site of origin, which we anticipate initiating in the first half of 2025.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
pembrolizumab. In addition to the option deal with Sairopa, some of our active research collaborations for biotherapeutics programs are with:
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
We have made significant progress under our research collaborations and in-licensing arrangements and believe we will continue to do so in 2025 and in future years. For example, in August 2024, we announced the initiation of a phase 1 clinical trial evaluating XB010, both as a monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors, following the FDA’s acceptance of our IND application, and enrollment is ongoing. XB010 is our first ADC advanced internally and consists of an MMAE payload conjugated to a mAb targeting the tumor antigen 5T4. XB010 was constructed using Catalent’s SMARTag site-specific bioconjugation platform, and its 5T4-targeting mAb was discovered in collaboration with Invenra. Over the next two years, we also intend to advance four additional biotherapeutic candidates toward potential IND filings, and each of these candidates was discovered, in part, in connection with our research collaborations and in-licensing arrangements, including: XB628, a bispecific antibody that targets both PD-L1 and NKG2A; XB371, a next-generation TF-targeting ADC that consists of a topoisomerase inhibitor payload conjugated to a mAb targeting TF; XB064, a high-affinity mAb that targets ILT2; and XB033, an ADC targeting the tumor antigen IL13Rα2.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
In August 2024, we announced that we will discontinue the development of XB002, our TF-targeting ADC, as part of our portfolio prioritization efforts. Based on available data, the compound is unlikely to improve upon tisotumab vedotin or other competitor TF-targeting ADCs currently in development. We plan to disclose data from the phase 1 JEWEL-101 study, evaluating XB002 in advance solid tumors, at a later date. We plan to reallocate resources to new pivotal trials with zanzalintinib, advancing XL309 and our growing pipeline.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
we expect to progress up to three new development candidates into preclinical development during 2025. We will continue to engage in pipeline expansion initiatives with the goal of discovering, acquiring and/or in-licensing promising investigational oncology assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
•In January 2024, we appointed Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. to our Board of Directors. Dr. Beckerle currently serves as Chief Executive Officer of the Huntsman Cancer Institute and Distinguished Professor of Biological and Oncological Sciences at the University of Utah. Dr. Eckhardt currently serves as Associate Dean of Experimental Therapeutics at Baylor College of Medicine and Associate Director of Translational Research at the College’s Dan L. Duncan Comprehensive Cancer Center.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RemovedMD&A
•In January 2024, we announced that our Board of Directors had authorized a corporate restructuring plan (the 2024 Restructuring Plan) to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities, including reducing real estate commitments and costs, and terminating certain licensing partnerships. The 2024 Restructuring Plan was initiated in the first quarter of 2024, and substantially completed in the second quarter of 2024.
Read it in 10-K Feb 11, 2025 at sec.govopen_in_new
RewordedMD&A
The increase decrease in cash, cash equivalents and marketable securities at December 31, 2024, 2025, as compared to December 31, 2023, 2024, was primarily due to cash inflows generated by our operations from sales of our products and our commercial collaboration arrangements, including $164.7 million in cash received from Ipsen for regulatory and commercial milestone payments earned, partially offset by cash payments to repurchase our common stock, cash payments to support our development and discovery programs, including acquisition of in-process research and development technology, tax payments and operating cash payments for employee-related expenditures and restructuring. restructuring, partially offset by cash inflows generated by our operations from sales of our products and our commercial collaboration arrangements.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
In addition to RCC, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC previously treated with sorafenib, and then in September 2021, March 2025, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy metastatic, well-differentiated pNET and who are RAI-refractory or ineligible. epNET.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in working capital as of December 31, 2024, 2025, as compared to December 31, 2023, 2024, was primarily due to the payments for repurchases of our common stock, partially offset by the favorable impact to our net current assets resulting from our increase in net product revenues and collaboration revenues, including a total of $164.7 million in milestone payments earned from Ipsen and reduction of the duration of our investments, partially offset by repurchases of our common stock. revenues.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in research and development expenses for the year ended December 31, 2024, 2025, as compared to 2023, 2024, was primarily related to decreases in license and other collaboration costs, clinical trial costs and other drug discovery costs, partially offset by an increase in other development costs, primarily related to manufacturing costs to support Exelixis’ our development candidates (presented as part of other development costs), partially offset by increases in consulting and clinical trial costs. outside services and stock-based compensation.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the EU, the United Kingdom K. and Canada, as a treatment for advanced RCC (both as a monotherapy and in combination with nivolumab) and for previously treated HCC and DTC indications.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been approved by the FDA FDA, and in 67 68 other countries: countries for all or a combination of, the following indications: as CABOMETYX® (cabozantinib) tablets for advanced RCC (both alone and in combination with BMS’ nivolumab (OPDIVO®)), for previously treated HCC and for HCC, previously treated, RAI-refractory DTC; DTC and previously treated, unresectable, locally advanced or metastatic, well-differentiated pNET and epNET; and as COMETRIQ® (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer. progressive MTC.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Beyond these biotherapeutics assets, we continue to make progress on multiple lead optimization preclinical programs for inhibitors of molecules that address a variety of targets targets, and that we believe play have significant roles in tumor growth, and we anticipate that some of these other programs could reach development candidate status in 2025 and beyond. potential for clinical differentiation.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Beyond these small molecule assets, we continue to make progress on multiple lead optimization programs for inhibitors of molecules that address a variety of targets targets, and that we believe play have significant roles in tumor growth, and we anticipate that some of these other programs could reach development candidate status in 2025 and beyond. potential for clinical differentiation.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, increased decreased for the year ended December 31, 2025, as compared to 2024, primarily due to lower costs associated with studies evaluating cabozantinib and XB002, partially offset by higher costs associated with zanzalintinib, XB628, XL309 and XB010 studies.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
We project our license collaboration services revenues may decrease in fiscal year 2025, 2026, as compared to 2024, 2025, primarily as a result of the anticipated achievement of fewer milestones a decrease in 2025, partially offset by development cost reimbursements and an increase in royalty revenues related to an increase in product payments on the sales of cabozantinib by Ipsen and Takeda.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Under this program, as As of the end of fiscal year 2024, December 31, 2025, we have repurchased $205.6 $1,159.7 million of our common stock, at an average price of $33.62 $38.39 per share. share under these SRPs and have completed the SRPs authorized in August 2024 and February 2025.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
RewordedMD&A
Beyond these assets, we continue to make progress on multiple lead optimization programs for inhibitors of a variety of targets that we believe play significant roles in tumor growth, and we We anticipate that some of these other programs could reach development candidate status in 2025 2026 and beyond.
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new
Quiet changesMD&A
License revenues primarily include:
Read it in 10-K Feb 10, 2026 at sec.govopen_in_new